| #62 |
Mark Schattenburg |
MIT |
1 |
| #62 |
Daniel K. O'Reilly, Jr. |
Emc Ip Holding Company |
1 |
| #62 |
John T. Foreman |
Q2100 |
1 |
| #62 |
Marco Fontecchio |
The Gillette Company |
1 |
| #62 |
Sachindra Kumar |
Actifio |
1 |
| #62 |
Jay Klemme |
Bose |
1 |
| #62 |
Michael Bruce Goldsmith |
RTX (Raytheon) |
1 |
| #62 |
Scott D. ESTES |
Genzyme |
1 |
| #62 |
Matthew R. Reome |
Cognex |
1 |
| #62 |
Guoyou Xu |
Enanta Pharmaceuticals |
1 |
| #62 |
Carol Iturralde |
Cisco |
1 |
| #62 |
Thomas Gaudette |
The Mathworks |
1 |
| #62 |
Robert M. Warden |
Aec-Able Engineering Co. |
1 |
| #62 |
Chen-Ping Su |
Orient Semiconductor Electronics, Limited |
1 |
| #62 |
Sateesh Nadabar |
Cognex Technology And Investment |
1 |
| #62 |
Kandarp Patel |
Futurewei Technologies |
1 |
| #62 |
Claudia Buser |
Genzyme |
1 |
| #62 |
Michael M. Lipp |
Civitas Therapeutics |
1 |
| #62 |
Robert Distel |
Dana-Farber Cancer Institute |
1 |
| #62 |
Christopher Paul Carroll |
Verizon |
1 |
| #62 |
Manisha Singh |
Meta |
1 |
| #62 |
Lev Volfson |
RTX (Raytheon) |
1 |
| #62 |
Sunpyo Hong |
Intel |
1 |
| #62 |
Shuwei Sun |
H.C. Starck |
1 |
| #62 |
David Looney |
Imperial College Innovations |
1 |
| #62 |
John Hey |
Alzheon |
1 |
| #62 |
Yingxuan Zhu |
Futurewei Technologies |
1 |
| #62 |
Socheavy D. Heng |
Emc Ip Holding Company |
1 |
| #62 |
Barry Berkowitz |
Temple Therapeutics Bv |
1 |
| #62 |
Mayur Kiran Patel |
Boston Scientific Scimed |
1 |
| #62 |
Nikolay I. Gishin |
I Sine |
1 |
| #62 |
J. Acquiles Sanchez |
Brandeis University |
1 |
| #62 |
Michael O'Callaghan |
Genzyme |
1 |
| #62 |
Nathaniel Steiger |
Respiratory Motion |
1 |
| #62 |
Jeff Karlson |
Irobot |
1 |
| #62 |
Matthew R. Shelton |
Microsoft |
1 |
| #62 |
Wolf Johnson |
Draper Laboratory |
1 |
| #62 |
Eric Johnsen |
— |
1 |